Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH MM 2018 | Updated POLLUX results for early relapsed myeloma patients

Saad Usmani, MD, of the University of North Carolina School of Medicine, Chapel Hill, NC, updates us at the European School of Haematology (ESH) International Conference on Multiple Myeloma 2018, held in Mandelieu, France, on the results from the POLLUX trial (NCT02076009). Dr Usmani describes the overall median survival, median progression-free survival, and measurable residual disease data in early relapsed myeloma patients receiving daratumumab, lenalidomide and dexamethasone treatment.